Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

Related Issuers

NEW ISSUE: Mehilainen E1.09bn sr sec 2-part, 7NC1 FRN and 7NC3 fixed, investor call Monday

HYC European Market: Deal Flow - General

Mehilainen Yhtiot Oy (AMBEAA) EUR1.09bn sr sec notes two-part. Expect B2/B/B (stable/stable/stable). Via GS (B&D)/Barc/Jefferies jt glocos/CVC/Danske/Nordea/RBI/SMBC/UniCredit/MUFG jt books. No reg rights. List ISE. NY law. SMR at 100 if the acquisitions have not closed by 06/30/26.

    - EUR TBD sr sec FRN due 2032 (7y). NC1 (MWC B+50bp), then at 100. Equity claw: 1y 40%. CoC at 101.

    - EUR TBD sr sec fixed-rate notes due 2032 (7y). NC3 (MWC B+50bp) (50%,25%,par). Equity claw: 3y 40%. Special call: 10% per year the 1st 3 years at 103. CoC at 101.

Investor call 10am UKT 06/09.  UOP: to finance the acquisition of Regina Maria (EUR691m cash and EUR292m repayment of Maria debt) and its sister company MediGroup (EUR89m cash) and EUR224m cash to the B/S. Also an additional equity contribution of up to EUR250m provided by CVC. Equity sponors: CVC and Hellman & Friedman (CVC and H&F have agreed to purchase shares of the parent company (TopCo) for total cash of EUR2bn on the acquisition closing date which will give CVC an approx 50% economic equity of TopCo and H&F an approx 30% economic equity of TopCo). Biz: provider of high quality and customer centric healthcare and social care services to the Finnish population and in increasing scale internationally, including Germany, Sweden, Estonia and Lithuania. HQ: Helsinki, Finland. (Acquisition announced 03/29/2025).

Netroadshow direct link: https://urldefense.com/v3/__https:/www.netroadshow.com/nrs/home/*!/?show=885cf08c__;Iw!!O2kDR7mm-zSJ!qa1pGC93H1dkwxSkdBzwRuw-qvDMOq8lGkSqbal5IxlkwJZHYQOLY0E_DWyJFmG9E8T-EhXVZIskoXRoAg$. Entry code: MEH2025.

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.